Zymeworks entered into a research agreement with XOMA to optimize an antibody. The partnership will leverage Zymeworks’ ZymeCAD™ suite of predictive protein engineering tools and XOMA’s Targeted Affinity Enhancement™ technology.
ZymeCAD molecular simulation platform creates a modeling environment that generates novel physical and chemical insights into protein systems, according to Zymeworks.
